This work is licensed under a <u>Creative Commons Attribution-NonCommercial-ShareAlike License</u>. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this site.



Copyright 2009, The Johns Hopkins University and John McGready. All rights reserved. Use of these materials permitted only in accordance with license rights granted. Materials provided "AS IS"; no representations or warranties provided. User assumes all responsibility for use, and all liability related thereto, and must independently review all materials for accuracy and efficacy. May contain materials owned by others. User is responsible for obtaining permissions for use from third parties as needed.



Section B

Two Sample z-test: Getting a p-value

Hypothesis Test to Compare Two Proportions

- Two sample z-test
- Are the proportions of infants contracting HIV within 18 months-ofbirth equivalent at the population level for those whose mothers are treated with AZT versus untreated (placebo)?
 - H_0 : $p_1 = p_2$
 - H_A : $p_1 \neq p_2$
- In other words, is the expected difference in proportions zero?
 - H_0 : $p_1 p_2 = 0$
 - H_{Δ} : $p_1 p_2 \neq 0$

Hypothesis Test to Compare Two Independent Groups

- Recall, general "recipe" for hypothesis testing . . .
 - 1. Start by assuming H_o true
 - 2. Measure distance of sample result from μ_0 (here again its 0)
 - 3. Compare test statistic (distance) to appropriate distribution to get p-value

$$z = \frac{(observed dif f) - (null dif f)}{SE of observed dif f erence}$$

$$z = \frac{\hat{p}_1 - \hat{p}_2}{S\hat{E}(\hat{p}_1 - \hat{p}_2)} = \frac{\hat{p}_1 - \hat{p}_2}{\sqrt{\frac{\hat{p}_1 \times (1 - \hat{p}_1)}{n_1} + \frac{\hat{p}_2 \times (1 - \hat{p}_2)}{n_2}}}$$

Infant HIV/ AZT Study

In the infant HIV/AZT study, recall:

$$\hat{p}_1 - \hat{p}_2 = -0.15$$

$$S\hat{E}(\hat{p}_1 - \hat{p}_2) = 0.036$$

So in this study:

$$z = \frac{-0.15}{0.36} \approx -4.2$$


 So this study result was 4.2 standard errors below the null mean of 0 (i.e., 4.2 standard errors from the difference in the proportion of HIV+ infants between the AZT and placebo groups expected if null was true)

How Are p-values Calculated?

- Is a result 4.2 standard errors below 0 unusual?
 - It depends on what kind of distribution we are dealing with
- The p-value is the probability of getting a test statistic as (or more extreme than) what you observed (-4.2) by chance
- The p-value comes from the sampling distribution of the difference in two sample proportions
- What is the sampling distribution of the difference in sample means?
 - If both groups are large then this distribution is approximately normal
 - This sampling distribution will be centered at true difference,
 - Under null hypothesis, this true difference is 0

Diet/Weight Loss Sample

To compute a p-value, we would need to compute the probability of being 4.2 or more standard errors away from 0 on a standard normal curve




AZT Study

- If we were to look this up on a normal table, we would find a very low p-value (p < .001)
- This method is also essentially equivalent to the chi-square $(\chi 2)$ method
 - Gives about the same answer (p-value)
 - This is how Stata approaches it
 - We will discuss chi-square method in more detail shortly: for now, just "take on faith" that it is equivalent so we can show you how to get the p-value, 95% CI (etc.) using Stata

To Do in Stata: Display Data in a 2x2 Table

- Stata "thinks" of data in a 2x2 (contingency) table
- Two rows and two columns



To Do in Stata: Display Data in a 2x2 Table

- We can get Stata to give us a 95% CI for the difference in proportions, and a p-value by using the csi command
- Syntax csi a b c d
 - Based a 2x2 table using our sample results as such

		Exposure		
		Yes	No	
Outcome	Yes	a	b	
	No	С	d	

csi 13 40 167 143

		Drug Group		
		AZT	Placebo	٦
HIV Transmission	Yes	13	40	53
	No	167	143	310
		180	183	363

Results from *csi* command

. csi 13 40 167 143

	Exposed	Unexposed	Total	
Cases Noncases	13 167	40 143	53 310	
Total	180	183	363	
Risk	.0722222	.2185792	1 .1460055	
	Point	estimate	[95% Conf	. Interval]
Risk difference Risk ratio Prev. frac. ex. Prev. frac. pop	146357 .3304167 .6695833 .3320248		2171766 .1829884 .4033765	
-	(chi2(1) =	15.59 Pr>ch:	i2 = 0.0001

Results from *csi* command

. csi 13 40 167 143

	-	Unexposed	Total	
Cases Noncases	13			
Total	180	183	363	
Risk	.0722222	.2185792	.1460055	
	Point	estimate	[95% Conf.	Interval]
Risk difference Risk ratio				0755374 .5966235
Prev. frac. ex. Prev. frac. pop			.4033765	
+		chi2(1) =	15.59 Pr>chi	2 = 0.0001

Results from *csi* command

. csi 13 40 167 143

	Exposed	Unexposed	Total	
Cases Noncases		40 143	53	
Total	180	183	363	
Risk	.0722222	.2185792	.1460055	
	Point estimate		[95% Conf.	Interval]
Risk difference Risk ratio Prev. frac. ex. Prev. frac. pop	146357 .3304167 .6695833 .3320248		2171766 .1829884 .4033765	
chi2(1) = 15.59 Pr>chi2 = 0.000				2 = 0.0001

Statistical method

"We conducted a randomized, double-blind, placebo-controlled trial of the efficacy and safety of zidovudine (AZT) in reducing the risk of maternal-infant HIV transmission"

Statistical method

- The proportion of infants diagnosed as HIV positive within 18 months of birth was compared between the AZT and placebo groups using a two-sample z-test of proportions
- 95% confidence intervals were computed for the 18-month infection proportion in each group and for the difference in proportions between both groups

Results

- The proportion of infants who tested positive for HIV within 18 months of birth was seven percent (95% CI 4 -12%) in the AZT group and twenty-two percent in the placebo group (95% CI 16 28%)
- This difference is statistically significant (p < .001)

Results

The study results estimate the decrease in the proportion of HIV positive infants born to HIV positive mothers associated with AZT to be as low as 8% and as high as 22%